Phathom Pharmaceuticals, Inc. cotiza a 7.00 USD y tiene una capitalización bursátil de $566M. En los últimos 12 meses ha facturado $240M con un margen de flujo de caja libre del -95.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartbu…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | — | $-0.18 | $-0.08 |
| Estimado | $0.04 | $-0.09 | $-0.19 | $-0.19 |
| Sorpresa | — | — | +5.3% | +57.9% |
| Métrica | PHAT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 87.1% | 57.0% | +30.1% |
| Operating Margin | -91.4% | -38.6% | -52.7% |
| Net Margin | -126.3% | -33.6% | -92.8% |
| FCF Margin | -95.4% | -13.9% | -81.5% |
| ROE | — | -40.4% | — |
| ROA | -85.4% | -32.0% | -53.4% |
| Current Ratio | 1.73 | 2.84 | -1.11 |
| Debt / Equity | -0.48 | 0.28 | -0.76 |